Plasma ATG5 is increased in Alzheimer’s disease

Sun Jung Cho, Hyun Joung Lim, Chulman Jo, Moon Ho Park, Changsu Han, Young Ho Koh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Alzheimer’s disease (AD) is a major cause of dementia. Growing evidence suggests that dysregulation of autophagy, a cellular mechanism essential for self-digestion of damaged proteins and organelles, is involved in neurological degenerative diseases including AD. Previously, we reported that autophagosomes are increased in the brains of AD mouse model. However, the plasma levels of autophagic markers have not yet been investigated in patients with AD. In this study, we investigated the expression of autophagy-related genes 5 and 12 (ATG5 and ATG12, respectively) in cells in vitro upon amyloid-beta (Aβ) treatment and in the plasma of AD patients. ATG5-ATG12 complex levels were increased in primary rat cortical neurons and human umbilical vein endothelial cells after Aβ treatment. Furthermore, we compared plasma from 69 patients with dementia, 82 patients with mild cognitive impairment (MCI), and 127 cognitively normal control participants. Plasma levels of ATG5 were significantly elevated in patients with dementia (149.3 ± 7.5 ng/mL) or MCI (152.9 ± 6.9 ng/mL) compared with the control subjects (129.0 ± 4.1 ng/mL) (p = 0.034, p = 0.016, respectively). Our results indicate that alterations in the plasma ATG5 levels might be a potential biomarker in patients at risk for AD.

Original languageEnglish
Article number4741
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Alzheimer Disease
Dementia
Autophagy
Human Umbilical Vein Endothelial Cells
Brain Diseases
Amyloid
Organelles
Proteolysis
Biomarkers
Neurons
Therapeutics
Genes
Cognitive Dysfunction

ASJC Scopus subject areas

  • General

Cite this

Plasma ATG5 is increased in Alzheimer’s disease. / Cho, Sun Jung; Lim, Hyun Joung; Jo, Chulman; Park, Moon Ho; Han, Changsu; Koh, Young Ho.

In: Scientific Reports, Vol. 9, No. 1, 4741, 01.12.2019.

Research output: Contribution to journalArticle

Cho, Sun Jung ; Lim, Hyun Joung ; Jo, Chulman ; Park, Moon Ho ; Han, Changsu ; Koh, Young Ho. / Plasma ATG5 is increased in Alzheimer’s disease. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{c26f763ce45644bead2b0e8b15efe7b1,
title = "Plasma ATG5 is increased in Alzheimer’s disease",
abstract = "Alzheimer’s disease (AD) is a major cause of dementia. Growing evidence suggests that dysregulation of autophagy, a cellular mechanism essential for self-digestion of damaged proteins and organelles, is involved in neurological degenerative diseases including AD. Previously, we reported that autophagosomes are increased in the brains of AD mouse model. However, the plasma levels of autophagic markers have not yet been investigated in patients with AD. In this study, we investigated the expression of autophagy-related genes 5 and 12 (ATG5 and ATG12, respectively) in cells in vitro upon amyloid-beta (Aβ) treatment and in the plasma of AD patients. ATG5-ATG12 complex levels were increased in primary rat cortical neurons and human umbilical vein endothelial cells after Aβ treatment. Furthermore, we compared plasma from 69 patients with dementia, 82 patients with mild cognitive impairment (MCI), and 127 cognitively normal control participants. Plasma levels of ATG5 were significantly elevated in patients with dementia (149.3 ± 7.5 ng/mL) or MCI (152.9 ± 6.9 ng/mL) compared with the control subjects (129.0 ± 4.1 ng/mL) (p = 0.034, p = 0.016, respectively). Our results indicate that alterations in the plasma ATG5 levels might be a potential biomarker in patients at risk for AD.",
author = "Cho, {Sun Jung} and Lim, {Hyun Joung} and Chulman Jo and Park, {Moon Ho} and Changsu Han and Koh, {Young Ho}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-41347-2",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Plasma ATG5 is increased in Alzheimer’s disease

AU - Cho, Sun Jung

AU - Lim, Hyun Joung

AU - Jo, Chulman

AU - Park, Moon Ho

AU - Han, Changsu

AU - Koh, Young Ho

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Alzheimer’s disease (AD) is a major cause of dementia. Growing evidence suggests that dysregulation of autophagy, a cellular mechanism essential for self-digestion of damaged proteins and organelles, is involved in neurological degenerative diseases including AD. Previously, we reported that autophagosomes are increased in the brains of AD mouse model. However, the plasma levels of autophagic markers have not yet been investigated in patients with AD. In this study, we investigated the expression of autophagy-related genes 5 and 12 (ATG5 and ATG12, respectively) in cells in vitro upon amyloid-beta (Aβ) treatment and in the plasma of AD patients. ATG5-ATG12 complex levels were increased in primary rat cortical neurons and human umbilical vein endothelial cells after Aβ treatment. Furthermore, we compared plasma from 69 patients with dementia, 82 patients with mild cognitive impairment (MCI), and 127 cognitively normal control participants. Plasma levels of ATG5 were significantly elevated in patients with dementia (149.3 ± 7.5 ng/mL) or MCI (152.9 ± 6.9 ng/mL) compared with the control subjects (129.0 ± 4.1 ng/mL) (p = 0.034, p = 0.016, respectively). Our results indicate that alterations in the plasma ATG5 levels might be a potential biomarker in patients at risk for AD.

AB - Alzheimer’s disease (AD) is a major cause of dementia. Growing evidence suggests that dysregulation of autophagy, a cellular mechanism essential for self-digestion of damaged proteins and organelles, is involved in neurological degenerative diseases including AD. Previously, we reported that autophagosomes are increased in the brains of AD mouse model. However, the plasma levels of autophagic markers have not yet been investigated in patients with AD. In this study, we investigated the expression of autophagy-related genes 5 and 12 (ATG5 and ATG12, respectively) in cells in vitro upon amyloid-beta (Aβ) treatment and in the plasma of AD patients. ATG5-ATG12 complex levels were increased in primary rat cortical neurons and human umbilical vein endothelial cells after Aβ treatment. Furthermore, we compared plasma from 69 patients with dementia, 82 patients with mild cognitive impairment (MCI), and 127 cognitively normal control participants. Plasma levels of ATG5 were significantly elevated in patients with dementia (149.3 ± 7.5 ng/mL) or MCI (152.9 ± 6.9 ng/mL) compared with the control subjects (129.0 ± 4.1 ng/mL) (p = 0.034, p = 0.016, respectively). Our results indicate that alterations in the plasma ATG5 levels might be a potential biomarker in patients at risk for AD.

UR - http://www.scopus.com/inward/record.url?scp=85063354210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063354210&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-41347-2

DO - 10.1038/s41598-019-41347-2

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 4741

ER -